logo
Prime Medicine Announces Pricing of Public Offering

Prime Medicine Announces Pricing of Public Offering

Yahoo19 hours ago
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions.
TD Cowen and BMO Capital Markets are acting as joint book-running managers for the offering.
The shares of common stock are being offered by Prime Medicine pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov.
The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine's beliefs and expectations regarding: the timing and closing of the public offering. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Prime Medicine's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine's views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor and Media Contacts
Gregory DearbornPrime Medicine857-209-0696gdearborn@primemedicine.com
Hannah DeresiewiczPrecision AQ212-362-1200hannah.deresiewicz@precisionaq.com擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Arm AI Ambitions Grow, But Analysts Warn Of Margin Trouble Ahead
Arm AI Ambitions Grow, But Analysts Warn Of Margin Trouble Ahead

Yahoo

time4 minutes ago

  • Yahoo

Arm AI Ambitions Grow, But Analysts Warn Of Margin Trouble Ahead

Arm Holdings (NASDAQ:ARM) underwhelmed with its latest quarterly results, prompting Wall Street analysts to revise their ratings on the chip designer. The company reported fiscal first-quarter revenue of $1.053 billion, up 12% year-over-year. It missed analyst estimates of $1.055 billion. Arm reported first-quarter adjusted earnings of 35 cents per share, which is in line with analyst estimates. Also Read: Arm expects second-quarter revenue of $1.01 billion to $1.11 billion, compared to estimates of $1.056 billion. The company anticipates second-quarter adjusted earnings of 29 cents to 37 cents per share, compared to estimates of 35 cents per share. Analyst Reaction Needham analyst Charles Shi reiterated a Hold rating for ARM. Rosenblatt analyst Kevin Cassidy maintained a Buy rating and a $180 price forecast for ARM. Goldman Sachs analyst James Schneider reiterated ARM with a Neutral rating and reduced the price forecast from $160 to $150. JPMorgan analyst Harlan Sur maintained a rating of Overweight for ARM and increased the price forecast from $150 to $175. Needham: Shi sees Arm's first-quarter results and second-quarter guidance as primarily in line with expectations. While full-year revenue expectations remain unchanged, guidance now suggests a weaker third quarter and stronger fourth quarter. Licensing revenue, Shi says, offsets softer royalties due to weak smartphone trends. Arm is transitioning from a pure IP licensing model to a product-centric approach, likely involving chiplet or full-chip development. This shift, driven partly by expanded design services revenue from SoftBank, pushes operating expenses higher—raising fiscal 2026 OpEx by around $100 million. Shi believes this transformation could pressure earnings soon, even as it signals a bold strategic pivot with long-term implications. Rosenblatt: Cassidy views Arm's first-quarter fiscal 2026 results as roughly in line with expectations, though earnings guidance came in slightly below consensus due to increased R&D spending, primarily to support its growing relationship with SoftBank. Cassidy remains optimistic that this investment will yield a positive return, particularly in AI data center applications. He highlights the strong momentum of Arm's Compute Subsystem (CSS), which helps customers bring AI-enabled products to market faster and supports higher royalty rates. First-quarter revenue of $1.053 billion, driven by a 25% year-over-year rise in royalties, slightly exceeded forecasts. While license revenue dipped 1%, this was expected due to timing shifts. Cassidy forecasted continued growth from AI, hyperscaler deployments, and Arm's expanding product partnerships. Goldman Sachs: Schneider sees Arm's latest quarterly results as primarily in line with expectations, but believes the stock may face near-term pressure. While revenue and EPS matched Street estimates, royalty revenue came in below forecast, and management's updated guidance pointed to slower royalty growth and elevated operating expenses. Schneider notes that expectations were high going into the report, driven by optimism around AI deployments and smartphone recovery. However, lower visibility in smartphone demand and deferral of royalty recognition have tempered the outlook. Arm is well-positioned for long-term gains in data centers and benefits from increasing royalty rates. Still, Schneider remains Neutral on the stock. He cut his EPS estimates by 6% and lowered his price forecast, citing limited near-term upside and high valuation. JPMorgan: Arm's fiscal first-quarter 2026 results as in line with expectations. Substantial licensing revenue helped offset weaker royalties tied to soft smartphone demand. For the September quarter, Arm guided revenue of $1.06 billion—matching consensus—but EPS guidance of 33 cents missed expectations due to higher operating expenses. While full-year revenue expectations remain unchanged, management now expects royalty growth to come in at the low end of its prior 10–15% range. Sur remains impressed by Arm's success with its Compute Subsystem (CSS) architecture, which generates royalty rates above 10%, but expresses concern over the company's push into full chip development. He warns this could erode margins and potentially alienate key customers. Price Action: ARM stock is down by 13.8% at $140.78 at the last check on Thursday. Read Next:Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Arm AI Ambitions Grow, But Analysts Warn Of Margin Trouble Ahead originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

Why S&P Global (SPGI) Earns a Strong Buy Rating from Analysts and Dividend Investors
Why S&P Global (SPGI) Earns a Strong Buy Rating from Analysts and Dividend Investors

Yahoo

time4 minutes ago

  • Yahoo

Why S&P Global (SPGI) Earns a Strong Buy Rating from Analysts and Dividend Investors

S&P Global Inc. (NYSE:SPGI) is included among the Best Strong Buy Dividend Stocks to Invest in Now. A group of analysts studying data on a large monitor. S&P Global doesn't operate in the spotlight like many other stocks. Instead, it functions behind the scenes as a key part of the financial system. Its four interconnected divisions— S&P Ratings, S&P Indices, S&P Market Intelligence, and S&P Commodity Insights— play a central role in how capital is priced, allocated, and tracked around the world. Although its presence may seem subtle, its reach is extensive. More than $100 trillion in assets follow its indices, 95% of bond investors rely on its ratings, and numerous ETFs pay licensing fees to use its benchmarks. The acquisition of IHS Markit has significantly strengthened S&P Global Inc. (NYSE:SPGI)'s data capabilities, enhancing its offerings with AI-driven analytics, more advanced terminals, and deeper market insights. This allows clients to anticipate market trends rather than just report on them. S&P's business relies on intellectual property rather than heavy capital investment. Its true strengths lie in its content, technology, and reputation. This model supports gross margins above 70%, strong recurring revenue, low customer turnover, and solid pricing power. In addition to this, S&P Global Inc. (NYSE:SPGI) is a strong dividend stock. On June 25, the company declared a quarterly dividend of $0.96 per share, which was in line with its previous dividend. Overall, it has raised its payouts for 53 years in a row. As of July 29, the stock has a dividend yield of 0.72%. While we acknowledge the potential of SPGI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lumen narrows loss, lifts free cash flow forecast on tax savings
Lumen narrows loss, lifts free cash flow forecast on tax savings

Yahoo

time4 minutes ago

  • Yahoo

Lumen narrows loss, lifts free cash flow forecast on tax savings

By Akash Sriram (Reuters) -Lumen Technologies on Thursday reported a smaller-than-expected second-quarter loss and raised its full-year free cash flow forecast by more than 60%, helped by cost savings from President Trump's tax cut legislation. The telecom and networking firm posted an adjusted loss of 3 cents per share, compared with analysts' expectations of a 26-cent loss, according to data compiled by LSEG. Lumen now expects 2025 free cash flow between $1.2 billion and $1.4 billion, up from a prior range of $700 million to $900 million. "We're taking it up considerably because of strong performance, but also because of the new tax bill, that definitely benefited us and that allows us to invest," CFO Chris Stansbury told Reuters in an interview. The new tax law enables companies such as Lumen to deduct more interest expenses and speed up how quickly they write off big investments, boosting near-term cash flow. Revenue for the quarter ended June 30 was $3.09 billion, slightly below analysts' average estimate of $3.11 billion. The shortfall included a $46 million giveback tied to the FCC's Rural Digital Opportunity Fund (RDOF), following the sale of Lumen's consumer fiber business to AT&T. Lumen agreed in May to sell its consumer fiber business to AT&T for $5.75 billion in cash, a move aimed at sharpening its enterprise focus and reducing capital expenditures. The company also recorded a one-time non-cash goodwill impairment charge of $628 million tied to the divestiture, contributing to a net loss of $915 million for the quarter. Stansbury said the divestiture would reduce annual capital expenditures by about $1 billion while trimming adjusted core earnings by $150 million. Lumen reaffirmed its full-year adjusted EBITDA guidance of $3.2 billion to $3.4 billion and said it expects to reach the high end of that range. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store